PMID- 30317792
OWN - NLM
STAT- MEDLINE
DCOM- 20190329
LR  - 20190329
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 26
IP  - 8
DP  - 2018 Aug 20
TI  - [Mechanism of angiotensin II (Ang II) on the proliferation of human hepatoma cell 
      line HepG2 cells].
PG  - 601-606
LID - 10.3760/cma.j.issn.1007-3418.2018.08.008 [doi]
AB  - Objective: To study the effect and mechanism of angiotensin (Ang II) on the 
      proliferation of human hepatocellular carcinoma HepG2 cells. Methods: The effects 
      of different concentrations of Ang II's (10(-8)-10(-4) mol/L) on proliferated 
      hepatocellular carcinoma HepG2 cells were detected by CCK-8 assay. The expression 
      of angiotensin II type 1 receptor (AT1) protein and activation of ERK1/2 protein 
      in hepatocellular carcinoma HepG2 cells after processing with Ang II were assayed 
      by Western blot. The cells were pretreated with candesartan (AT1 receptor 
      antagonist), sorafenib (Raf kinase inhibitor) and PD98059 (ERK1/2 inhibitor) for 
      1.5 h and then Ang II (10(-6) mol/L) was added. CCK-8 assay was used to determine 
      whether it could reverse the proliferation of Ang II, and ERK phosphorylation 
      levels were detected by Western blot. The changes in Bcl-2 and c-myc gene 
      expression before and after Ang II processing were detected by Rt-PCR. According 
      to different data, t-test, one-way analysis of variance or SNK method were used 
      for statistical analysis. Results: HepG2 cells treated with different 
      concentrations of Ang II promoted cell proliferation after 24h and 48h. After 24 
      h, cell vitality was strongest with Ang II concentration 10(-5) mol/L and the 
      absorbance value was 0.990 8+/-0.097 8; and again after 48 h, the cell viability 
      was strongest with Ang II concentration 10(-6) mol/L and the absorbance value was 
      1.302 7 +/- 0.030 9. Moreover, the pro-proliferation effect of Ang II on HepG2 
      cells blocked candesartan, sorafenib and ERK1/2 isolated inhibitors. After 
      treatment with 10(-6) mol/L Ang II, Western blot showed that Ang II significantly 
      promoted AT1 receptor expression and phosphorylation of ERK1/2 protein confirmed 
      that Ang II activated the AT1/RAF/ERK1/2 signaling pathway. In addition, Rt-PCR 
      detection showed that the downstream of Bcl-2 and c-myc genes expressions rose 
      significantly when the concentration of Ang II ranged from 10(-8) to 10(-6) 
      mol/L. Conclusion: Ang II can promote the proliferation of HepG2 cells by 
      activating AT1/Raf /ERK1/2 signaling pathway and enhance the downstream of Bcl-2 
      and c-myc gene expression.
FAU - Qi, R
AU  - Qi R
AD  - Youyi Hospital, Dalian Medical University, Dalian 116000, China.
FAU - Lei, C G
AU  - Lei CG
AD  - Department of Hepabilary Surgery, Qingdao Muliciple Hosptisal, Qingdao 266071, 
      China.
FAU - Bai, Y X
AU  - Bai YX
AD  - Xinhua Hospital, Dalian Medical University, Dalian 116000, China.
FAU - Xing, X
AU  - Xing X
AD  - Department of Hepabilary Surgery, Qingdao Muliciple Hosptisal, Qingdao 266071, 
      China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 11128-99-7 (Angiotensin II)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Carcinoma, Hepatocellular
MH  - Cell Line
MH  - Cell Proliferation/*drug effects
MH  - Cells, Cultured
MH  - Genes, bcl-2/*drug effects/genetics
MH  - Genes, myc/*drug effects/genetics
MH  - Hep G2 Cells/*drug effects
MH  - Humans
MH  - Liver Neoplasms
MH  - Reverse Transcriptase Polymerase Chain Reaction
OTO - NOTNLM
OT  - Angiotensin II
OT  - Angiotensin type 1 receptor
OT  - Carcinoma, hepatocellular
OT  - Extrallular signal-regulated kinase 1/2
OT  - Raf
EDAT- 2018/10/16 06:00
MHDA- 2019/03/30 06:00
CRDT- 2018/10/15 06:00
PHST- 2018/10/15 06:00 [entrez]
PHST- 2018/10/16 06:00 [pubmed]
PHST- 2019/03/30 06:00 [medline]
AID - 10.3760/cma.j.issn.1007-3418.2018.08.008 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2018 Aug 20;26(8):601-606. doi: 
      10.3760/cma.j.issn.1007-3418.2018.08.008.